Evaluation of data relevance, reliability and contribution to uncertainty is crucial in regulatory health risk assessment if robust conclusions are to be drawn. Whether a specific study is used as key study, as additional information or not accepted depends in part on the criteria according to which its relevance and reliability are judged. In addition to GLP-compliant regulatory studies following OECD Test Guidelines, data from peer-reviewed scientific literature have to be evaluated in regulatory risk assessment of pesticide active substances. Publications should be taken into account if they are of acceptable relevance and reliability. Their contribution to the overall weight of evidence is influenced by factors including test organism, study design and statistical methods, as well as test item identification, documentation and reporting of results. Various reports make recommendations for improving the quality of risk assessments and different criteria catalogues have been published to support evaluation of data relevance and reliability. Their intention was to guide transparent decision making on the integration of the respective information into the regulatory process. This article describes an approach to assess the relevance and reliability of experimental data from guideline-compliant studies as well as from non-guideline studies published in the scientific literature in the specific context of uncertainty and risk assessment of pesticides.
Introduction
The human health risk assessment of pesticides is an essential part of the approval of active substances (AS) or the authorisation of plant protection products (PPP) and biocidal products (BP) in Europe according to the European legislation (Regulations (EC) No 1107/ 2009 and (EU) No. 528/2012) . Detailed listings of all data requirements are part of this legislation (e.g. Regulations (EU) No. 283/ 2013, (EU) No. 284/2013 (EU, 2013a EU, 2013b) ). In a complete dossier all data requirements have to be addressed by the applicant. This can be achieved either by using studies performed according to test guidelines and under GLP, which are often property of the applicant and remain unpublished, or based on research studies published in the scientific literature. In any case, data used for regulatory decisions have to be appropriate for the respective purpose (relevant) and trustworthy because of their quality (reliable).
Very often 200 studies or more are submitted for the assessment of human health, including toxicology, residues, application safety and classification & labelling. This does not take into account the assessment of the AS for efficacy and environmental effects, which can easily double this amount.
The evaluation of data reliability itself is a key point which can influence data selection, and thereby also the credibility and usefulness of a regulatory assessment. Therefore, a transparent evaluation tool for determining the relevance and reliability of study results is necessary.
Mandatory studies according to data requirements have to be performed according to harmonised OECD test guidelines (TG) or EU test methods. Furthermore, these studies have to be conducted according to Good Laboratory Practice (GLP) principles. Such studies are described in the following as "guideline-compliant studies". In addition, current EU legislation mandates regulatory agencies to take published data (e.g. peer-reviewed scientific publications) into consideration for human health risk assessment of pesticides (EC, 2009; EU, 2012) . A literature search and review of the available publications has therefore become a mandatory part
Systems for evaluation of data quality
The criteria used for the assessment of relevance and reliability are a central issue in the process of systematic literature reviews (see Fig. 1 ).
Different systems have been developed and applied for the evaluation of data quality in the past. For the assessment of chemicals, a now widely known system was developed by Klimisch et al. (1997) . In this approach the most important parameter for unrestricted reliability was seen in the adherence to harmonised TGs and GLP principles. Studies are assigned to four categories: 1 -Reliable without restriction; 2 -Reliable with restriction; 3 -Not reliable; 4 -Not assignable. Today, a modification of these principles is recommended by ECHA for the assessment of biocide AS, as well as for chemicals under REACH (ECHA, 2011; ECHA, 2015) . One important criticism of the criteria in Klimisch et al. (1997) is that they introduce a bias in favour of the use of GLP-and TG-studies (Buonsante et al., 2014; Myers et al., 2009 ). Critics also claim that when these criteria are applied without adjustment to nonguideline studies, results may often be categorized as "reliable with restriction" or "not reliable", despite being of high scientific value.
In the EU, a wide consensus was reached among member states that categories leading to decisions on reliability have to be filled with more specific, transparent and appropriate criteria (EC, 2015) . Thus, further development and harmonisation of criteria is urgently needed.
Several tools have been developed to assess the reliability of studies, including ToxRTool (Schneider et al., 2009) and SciRAP . Both consist of a series of specific questions concerning key points of the described experiments, which have to be answered by scoring. These systems allow a more transparent documentation of the study evaluation by the assessor and do not emphasize the use of harmonised TGs.
ToxRTool (Toxicological data Reliability assessment Tool) is an MS Excel based tool with comprehensive systems for scoring of in vitro as well as in vivo studies. It makes clear reference to the four categories used by Klimisch, but contains a more specifically phrased questionnaire (Schneider et al., 2009) .
SciRAP (Science in Risk Assessment and Policy), which focuses on in vivo studies, proposes a more integrated approach allowing assessment of both relevance and reliability. It uses scoring for the questions, which are separated into reporting quality and methodological quality, but does not lead to a final score for the whole study. According to the authors, one of the reasons is to avoid dismissal of studies as a result of too strict criteria Molander et al., 2014) .
A very broad and comprehensive overview on frameworks used for evaluating relevance and reliability has recently been published by Roth and Ciffroy (2016) . Ågerstrand and Beronius (2016) reviewed the regulatory basis for the implementation of systematic review approaches in many regulatory fields.
Relevance
Relevance evaluation determines whether a study or publication should be included or excluded for a specific regulatory purpose or whether a weight of evidence approach should be used when addressing a precisely formulated question. In systematic review approaches, an initial relevance check is carried out based on titles and abstracts of retrieved literature. Per se, all data that contain information on the substance or product under assessment and that concern the problem under assessment are relevant. However, the actual use for regulatory purposes depends also on reliability of the data.
According to EFSA, studies relevant for regulatory purposes are those that address the data requirement(s) set out in the respective regulations on hazard identification, hazard characterisation or exposure assessment (EFSA, 2011) . ECHA defines relevance as "the extent to which data and tests are appropriate for a particular hazard identification or risk characterization" (ECHA, 2011) . It is important to understand that the relevance of a study depends mainly on the scientific or regulatory question under assessment and the suitability of the study to address this question. Studies meeting regulatory data requirements will be most likely considered relevant but relevance is not confined to those. In contrast, studies which exceed data requirements or address additional issues may be also of scientific and regulatory importance.
Important criteria for assessing the relevance of information for toxicological risk assessment have been proposed in three guidance documents for chemicals, PPP and BP (ECHA, 2011; ECHA, 2015; EFSA, 2011) . Based on these approaches, a set of questions addressing relevance was compiled (Table 1) , which has to be addressed prior to reliability within an iterative process. If the study is considered not relevant, it will not be necessary to assess its reliability.
Reliability
Reliability evaluation influences the weight that is attributed to the presented results. Consequences of reliability scoring depend upon the whole data package and have to be decided case-by-case for each dossier. Even when no studies or publications of unrestricted reliability are available, a weight of evidence evaluation can still allow one to draw sound and robust conclusions from available and congruent data with restricted reliability (ECHA, 2010).
According to EFSA, study reliability "concerns methodological quality and refers to the extent to which a study is free from bias and its findings reflect true facts" (EFSA, 2011) . ECHA defines reliability as "evaluating the inherent quality of a test report or publication relating to preferably standardised methodology and the way the experimental procedure and results are described to give evidence of the clarity and plausibility of the findings. Reliability of data is closely linked to the reliability of the test method used to generate the data" (ECHA, 2011; Klimisch et al., 1997) .
Thus, in contrast to relevance, reliability is an inherent property of a study, which includes the use of well-founded scientific approaches, the avoidance of bias within the study design and faithful study conduct and documentation.
Good Laboratory Practice (GLP) and Good Scientific Practice (GSP)
The implementation of "Good Laboratory Practice" (GLP) principles was originally motivated by fraudulent practices leading to falsified study results being fed into regulatory processes (Budiansky, 1983) . GLP aimed to preclude such practices and improve the quality of regulatory decisions. Adherence to GLP principles is also an essential basis for the "mutual acceptance of data", intended, among other purposes, to avoid duplication of animal testing (OECD, 1997) . Despite these clear advantages, putting a high weight on adherence to GLP principles has been heavily criticised as this would lead to a lower acceptance of non-GLP The first three steps result in the identification of publications with relevance to the assessed question by suitable search strategies. Subsequently, a reliability evaluation is performed (step 4). Steps five to eight concern data collection and synthesis, presentation and interpretation of results as well as final conclusions to be drawn. All studies assessed as relevant and reliable have to be included into the risk assessment. As a standard procedure, such a systematic literature review is performed for the respective period of interest usually 10 years before application. Characteristics of the study design, including test organism/in vitro model, have to be taken into account with respect to the regulatory question addressed. 4 Are the methods adequate for the investigation of the endpoint(s)?
STEPS 1&2
The methods used may be more or less relevant for addressing the regulatory question. For example, effects like activation of a signalling cascade measured by mRNA expression of marker genes may point to proliferative changes, but are considered less relevant than the proof on cellular level. 5 Is the route of exposure suitable to sufficiently characterise a potential effect?
For a thorough toxicological evaluation, data on all relevant exposure routes are needed. For pesticides especially, oral route for dietary exposure and dermal/inhalation for application safety are important. 6 Are test concentrations relevant in the context of the addressed problem?
The applied doses should be appropriate to evaluate the risk with regard to the expected exposure. Although TGs may require the highest dose to induce adverse effects independent of expected exposure, for the prediction of risks at the level of expected human exposure such excessive doses may be irrelevant. 7 Is the duration of exposure appropriate for the endpoint(s) being investigated?
The duration of exposure should be appropriate for addressing the particular endpoint (e.g. acute response vs. chronic response, developmental susceptibility windows, etc.).
studies for regulatory purposes, thereby excluding or disregarding many non-guideline studies from research institutes as these might not hold GLP certificates (Buonsante et al., 2014; Myers et al., 2009 ).
Recommendations for "Good Scientific Practice" (GSP), which can to some degree be considered an equivalent to GLP recommendations, have been developed for the academic environment, e.g. by the German research council (Deutsche Forschungsgemeinschaft, DFG) or the Second World Conference on Research Integrity in 2010 (DFG, 2013; ESF, 2011) . These recommendations give guidance on the documentation and storage of primary and secondary data, on publication of results and require that institutions implement rules and structures assuring compliance to given standards. Similar GSP rules are increasingly implemented around the globe (BBSRC, 2013; MRC, 2012; NHMRC, 2007; NSF, 2009; PRCR, 2011) . In addition, criteria for good reporting of animal studies can be found in the ARRIVE guideline or the gold standard publication checklist (GSPC) (Hooijmans et al., 2010; Kilkenny et al., 2010) . In contrast to GLP, however, there are typically no audits to monitor adherence to GSP rules. Still, many scientific journals today require a declaration by the authors that these practices were respected. Such a declaration may be considered an appropriate equivalent to a GLP compliance statement and should suffice to assure an appropriate level of raw data documentation in the laboratory even though raw data is not necessarily part of the publication. Nevertheless, neither adherence to GLP nor to GSP guarantees methodological quality or error-free experimentation and data analysis. These aspects require further attention in the reliability assessment.
Evaluation of guideline-compliant studies
For guideline-compliant studies, the respective TGs and guidance documents provide harmonised "check lists" to assess the reliability of the study report. Deviations may reduce study reliability as described in Fig. 2 . The reliability of a study may be enhanced if the extent and sources of uncertainty are clearly addressed. Current guideline-compliant studies need to fulfil the following points that support the reliability of their data:
i) The experiments are carried out under GLP conditions.
ii) The methods used have been validated and their comparability, reproducibility, specificity and sensitivity has been confirmed. iii) All data are submitted in a non-aggregated form, allowing one to check the results of single measurements (e.g. blood parameters or body weight). iv) Information considered necessary for judging reliability of the presented data is requested in chapter "Data and Reporting" of the OECD TGs.
If no deviations from the TG are evident, reliability of a guideline-compliant study may be assumed. Deviations from TGs will not always have an impact on the assessment of an endpoint and studies carried out according to outdated TGs may deviate from current ones, but often still contain all necessary information for acceptance. If deviations are identified, they have to be reported, explained and transparently justified. If a study is flawed by severe deficiencies, it may become unacceptable for regulatory purposes (see Fig. 2 ). This appraisal is subject to expert judgement.
Evaluation of non-guideline studies
Evaluation of reliability and inclusion of non-guideline studies in a regulatory context needs to be performed and documented in a transparent and reproducible manner that is generally comparable to existing approaches for evaluation of guideline-compliant studies.
Most published toxicological studies have not been designed specifically to screen for hazard properties of chemical substances or to satisfy regulatory data requirements. Thus, the methodology used in the most published toxicological studies varies considerably and cannot easily be compared with the recommendations of a (OECD) TG.
Only in certain areas may general quality criteria, similar to those for guideline-compliant studies, be applicable to published studies (for example when standardised study designs are widely used as per in vitro gene mutation assays).
Instead, for the majority of studies, more generic criteria are needed. Such criteria are proposed in the following section. A process scheme is presented in Fig. 3 , analogous to the one for guideline-compliant studies. 
Criteria for guideline-compliant and non-guideline studies
Criteria for the evaluation of reliability of guideline-compliant or non-guideline studies are grouped into five topics and discussed in the following sections.
Test item identification
Basic information on the identity of the test item such as the substance or product name is a core criterion in terms of relevance for deciding on inclusion/exclusion of the particular study. However, more detailed information on the test item is required to evaluate whether the results of an assay can reliably be attributed to the actual substance or mixture under evaluation (see Table 2 ).
The composition of commercially available products is often modified over time as a result of adaptations to technical progress or market needs. Also, products of the same name sold in different countries may have different compositions. Without sufficient information, the toxicological properties found in a respective study might be wrongly attributed to the AS in such cases. Sometimes, information in the title or abstract of publications gives the impression that the pure AS was investigated where in fact the test item was a complex commercially available PPP or BP (e.g. Daruich et al., 2001; George et al., 2010; Karabay and Oguz, 2005) . These are no problems affecting the reliability of a study, but they certainly affect relevance for a certain regulatory question. Thus, the assessment of relevance may occasionally need to be revised during evaluation of reliability.
Test species and in vitro models
Transparent and comprehensive description of the test organism of an in vivo study or the model used in an in vitro study is in general essential information, not only for any subsequent regulatory use. Ågerstrand et al. (2011) examined nine studies on aquatic toxicity with regard to the description of the test organism and concluded that none of the publications covered all aspects under consideration. A common drawback is that certain information might not have been considered important by the author at the time of publication, but would be needed later by a regulatory authority to make the best possible use of the data, particularly when there is conflicting information from other sources.
For in vivo studies, the identification of the species, strain and sex of animals is required for rating systems as well as in the OECD TGs for the different study types. According to OECD TGs, also age, weight at start of the test as well as housing conditions and usually also source of the animals have to be covered. The questionnaire of ToxRTool includes similar criteria. SciRAP criteria in addition include very detailed questions on housing and feeding conditions that can provide background information on exposure to possible endocrine active substances.
It is well known that the genetic background can influence test results. Beside defined genetic modifications, it has also been shown in both mice and rats that intra-strain differences exist for inbred and outbred strains (e.g. Bryant et al., 2008; Langer et al., 2011) .
For in vitro studies, the situation is even more complex, as the multitude of models shows: for example, whole organs or organ slices, tissue samples or explants, cell cultures, bacteria or cell free assays. The criteria of ToxRTool include questions on the description of the test system, on the source/origin, on test system properties and on conditions of cultivation and maintenance. (Schneider et al., 2009) . Also in OECD TG for in vitro tests and other in vitro guidelines, many criteria have been listed that can be used as guidance. Table 3 summarises information required on test species and in vitro models.
Study design
Sufficient information on study design is requested by all existing rating systems and TGs. Important features for description of in vivo study design are given in Table 4 .
In a comparison carried out by Segal et al. (2015) using ToxRTool as rating system, the criterion "Are sufficient details of the administration scheme given to judge the study" was one of those with the most inconsistent responses among different evaluators. This underlines how important (and difficult) it is to describe the exposure conditions sufficiently. Information on study design is essential for the assessor to judge the appropriateness and limitations of the specific test.
For in vitro systems it is not feasible to present a comprehensive list of criteria meeting all demands and only few evaluation systems address in vitro studies. In principle, the basic considerations for in vivo studies are applicable also to in vitro studies, some specific items to be considered as applicable are included in Table 5 . Fig. 3 . Decision tree for the acceptability of non-guideline studies (expert judgement).
Documentation of test results
To be considered acceptable for regulatory purposes, test results need to be presented in a sufficiently accurate, detailed and comprehensible manner, irrespective of the study type.
In principle such an assessment is performed prior to publication by the respective journal for published scientific literature. However, there are currently no common standards that would guarantee the same level of assurance across journals and publications. For studies on endpoints covered by OECD (or other) TGs, detailed requirements for reporting of results can be found in the respective guideline documents. These recommendations as well as requirements common to the various TGs may be used to guide the reliability evaluation of studies for which such TGs do not exist. A compilation of important questions is given in Table 6 .
Evaluation including statistical methods
The statistical processing of data allows formalising the results and weighing their relevance in consideration of the study design. However, inappropriate statistical analysis of research data has been heavily criticised in the past. This was mainly attributed to formal application of statistical tests and generic significance levels (Ioannidis, 2005 ). An analysis of 30 recent publications from toxicological journals showed that few reports provided justifications for the statistical method selected and many failed to describe tests for normality and equal distribution when applying ANOVA or Student's T-test (Na et al., 2014) . It was noted that the positive predictive value, i.e. the probability that a positive finding is a true positive, also depends on the pre-study odds (i.e. the quality of the hypothesis tested) and the power of a study (Ioannidis, 2005) . Similarly, repeated and/or parallel multiple testing of a large range of endpoints increases the likelihood of false positives. Publication bias, i.e. that test results showing an effect are more likely to be reported, may then lead to an underestimation of the impact of repeated and parallel testing. Conversely, positive relationships may be missed as the result of high variability and/or unfavourable signal-to-noise ratios or application of inappropriate statistical methods (Ioannidis, 2005) and low group sizes in in vivo testing can be one reason for low statistical power and a lack of reproducibility. Accordingly, TGs and accompanying guidance frequently advise one to ensure that i) the statistical test chosen is appropriate for the data to be evaluated and ii) interpretation of the statistics takes into account the degree of certainty of the test result and the biological context (or at least relevance) of the finding. Extensive guidance has been developed on the topic and can be found for example in the OECD Guidance document no. 116 on the conduct and design of chronic toxicity and carcinogenicity studies (OECD, 2012) . Although this document specifically relates to the chronic and carcinogenicity tests in animals, key principles apply to the evaluation of study results in general, including those published in the open literature.
In descriptive statistics, calculation of means remains the most popular approach in toxicology to describe a tendency, accompanied by standard deviation or standard error of mean (Na et al., 2014) . However, depending on the distribution of the data, the -Minimum content (purity) of the substance -Numerical descriptors preferred (% w/w, g/kg).
-If applicable: isomeric ratios, presence of enantiomers, diastereomers 3 Is information on impurities of the test substance given?
-Information on potentially toxicologically relevant impurities (e.g. from the manufacturer via lot/batch number) that may influence the test result -Impurities present in the test substance/formulation should cover the impurity profile of the substance under assessment 4 Are relevant degradation products specified?
-Substances susceptible to deterioration may produce degradation products which affect the toxicological profile. -Analysis of potential confounding factors, which may influence the outcome of a toxicity study (e.g. phytoestrogen content of the diet; solvents that induce liver toxicity, feed contaminants, etc.). Methods 10 Are the methods for the determination of all parameters clearly described and adequate?
-Conclusive and detailed description of methods used in the research laboratories (validated or confirmed in inter-or intra-lab-comparisons, e.g. ring trials, etc.). -Information whether the method is widely accepted or whether modifications have been carried out in the reporting lab. 11 Are the analytical methods clearly described and adequate?
-Statement of specificity and sensitivity of the analytical methods. -Depending on the endpoints, negative or positive controls or both.
-Number of controls has to be sufficient for statistical power.
-Culture and handling to mimic that of treatment groups. 5 Are parameters measured adequate for investigation of the endpoints?
-Predictivity of changes in measured parameter(s) for the toxicological endpoint.
-Note: In vitro methods may address different parameters than in vivo studies. Administration 6 Is the method of application/details on the experimental set-up given?
-Comprehensible and clear description of the method of application and set-up.
-Sufficient information about frequency of applications and total duration of exposure -Appropriateness of type, frequency and duration of exposure for the aim of the study 7 Are the applied doses or concentrations in test medium given?
-Clear indication, whether given test concentrations refer to the whole formulation or to the active compound. -Information on the test concentrations, if possible analytically verified. 8 Is the vehicle described and adequate? -Description of the vehicle used to prepare dosing solution to conclude on potential vehicle effects on the test system itself or on the potency of the test item. 9 Were potential confounding factors addressed and/or obviated?
-Potential confounding factors, which may influence the outcome (e.g. compounds in cell culture material; FCS batches; solvents that induce liver toxicity like ethanol, etc.). Methods 10 Are the methods for the determination of all parameters clearly described and adequate?
-Sufficient detail on the methods required to assess reliability of the study results.
-Validation of methods, external/internal quality controls.
-Comparability to reference methods.
-Impact of method modifications. 11 Are the analytical methods described and adequate?
-Specificity and sensitivity of any analytical methods, e.g. for determination of test item concentrations, if applicable.
Examination of dose-response relationships may improve sensitivity and confidence in findings. For carcinogenicity studies, trend testing (e.g. using the Cochran-Armitage linear trend test) has become a routine approach (Gart et al., 1986; OECD, 2012) . However, it should be noted that the "shape" of the dose-response relationship can vary considerably and prior knowledge about the appropriate regression model is thus required. Inappropriate assumptions may result in a failure to identify a treatment related effect. Guidance on the selection of appropriate models has been developed in the context of benchmark dose modelling and may be applied more generally (U.S.EPA, 2012) .
Data evaluation should also take into account known confounders. While reduced survival in cancer bioassays may reduce the number of tumour bearing animals, cytotoxicity may either mask or induce other effects such as mutagenicity. To some extent, the confounding effect may be eliminated by choosing additional statistical tests (e.g., Peto test) or including alternative endpoints in the evaluation, such as time-to-tumour. Normalisation of data can be a viable option, for example, when there are effects on body weight.
Finally, it should be noted that the methodology of data analysis in toxicology is also subject to some, albeit slow modifications over time, reflecting scientific progress in the field (Kobayashi, 2001 ). Accordingly, results should be reported in sufficient detail to allow for re-analysis if indicated (see also section 4.4.4). Also, the fact that a lack of statistical significance does not prove an absence of an effect or activity is often neglected. To clarify the level of confidence of negative test outcomes, an assessment of the statistical power of an assay is necessary. However, the statistical power is rarely calculated or cited in the study report, even if available from method validation.
Criteria provided in Table 7 can assist when assessing the appropriateness of the statistical method(s) and documentation.
Uncertainty
A consideration of the sources of uncertainty that clearly and transparently states what sources of uncertainty were identified and how these affect the final conclusions should be included in an assessment. According to Fenner-Crisp and Dellarco (2016) , uncertainty is "a scientific reality that cannot be totally eliminated, and, therefore, must be acknowledged and explained, together with its impact on the risk conclusions and estimates". The WHO/ IPCS more specifically defined uncertainty in relation to hazard characterisation as "lack of knowledge regarding the "true" value of a quantity, lack of knowledge regarding which of several alternative model representations best describes a system of interest, or lack of knowledge regarding which probability distribution function and its specification should represent a quantity of interest" (WHO/ IPCS, 2014). As outlined by ECHA in REACH Guidance R.19, uncertainty can also relate to the presence or absence of intrinsic hazard properties of a substance (ECHA, 2012) . In agreement with this, EFSA described uncertainty as "a general term referring to all types of limitations in available knowledge that affect the range and probability of possible answers to an assessment question" (EFSA, 2016) .
Uncertainty in risk assessments can result from uncertainty in the measurement of (no) effect, uncertainty in the exposure -Access to primary data (i.e. original output files/tables providing OD readings rather than enzyme activity in IU/mL) in order to increase the transparency of the presented information for regulatory risk assessment. -Allows one to perform recalculation of results if needed, including standard curves. estimate, whether predicted or based on measurements, and uncertainty in the risk estimate e.g. resulting from extrapolation between or within species (ECHA, 2012) . These kinds of influences, lack of knowledge or lack of data as well as methodological limitations of the underlying study can provide sources of uncertainty. Uncertainty can also result from the transformation of continuous measurement data into dichotomous "yes/no" outputs, for example, as discussed for the LLNA in skin sensitisation testing (Kolle et al., 2013; Leontaridou et al., 2017 and others) largely ignoring the grey-zone in between. This has been addressed in recent revisions of genotoxicity test guidelines with the introduction of the categories clearly positive, positive, equivocal, etc. (OECD, 2016) .
When hazard data such as information from a second species or a valid long-term study is lacking, the increased uncertainty is frequently compensated for by application of additional assessment (or uncertainty) factors (ECHA, 2015) . However, uncertainty of a value derived from data is usually not explicitly taken into account when following the NOAEC/LOAEC approach. The utility of the benchmark dose approach, providing a lower confidence limit (BMDL) for a possible toxicological effect has been discussed frequently, but a final and harmonised methodology has not yet been broadly implemented.
It should be considered how the inclusion of studies with limited relevance and/or reliability may affect the uncertainty of the whole assessment. For example, when the tested formulation differs from the product under evaluation, the applicability of study results has to be examined according to the specific criteria given in EU Guidance SANCO/12638/2011 (EC, 2012 , thus limiting the introduction of uncertainty resulting from the limited relevance of the data. This shows how a thorough evaluation of relevance and reliability is required to identify and control for sources of uncertainty as much as possible.
Discussion and conclusion
We conclude that the contribution of non-guideline studies from peer-reviewed scientific literature to regulatory risk assessments could be substantially increased. Implementation of good reporting criteria and using transparent principles for study conduct; for example GSP, would augment the applicability of scientific publications. Within assessment reports or databases used for regulatory decision making, transparent evaluation of relevance and reliability of all available information is of major importance for reproducibility and public confidence and has to be well documented. Even though several systems for evaluation have been published, the need for harmonised criteria is still urgent.
The comparison of requirements included in OECD TGs and in the two evaluation tools SciRAP und ToxRTool (Schneider et al., 2009) shows that for non-guideline studies criteria catalogues are also applicable. These tools need to be employed regularly to become more widely accepted by risk assessors. Another recently published overview on important features of a high-quality assessment is the "Guide for Judging the Quality of an Assessment" by Fenner-Crisp and Dellarco (2016) in which the importance of applying predefined criteria and a weightof-evidence approach to address causal relationships in a systematic manner is advocated.
Original guideline-compliant studies from industry are usually not published or otherwise accessible and thus are not subject to critical review by the scientific community or the public (Lutter et al., 2013) . It would be more transparent to disclose the original, typically confidential study reports together with the raw data. After extensive public discussions concerning the assessment of the active substance glyphosate, EFSA recently started to release the raw data used in the assessment, following a public access to document request 1 . This will enable the professional public in particular to independently asses the conclusions of the regulatory authorities and the details of the assessment process.
In general, regulatory authorities fulfil their responsibility of transparency by making reports available, for example on their websites. These include compilations of the assessed data. Additionally, international authorities like the European EFSA and ECHA provide an immense amount of data on assessed substances (e.g. registered substances database 2 , EU Pesticides Database 3 ).
Despite this, regulatory reports are cited only very rarely in published literature. In many research facilities, little awareness seems to exist for the fact that scientific assessments by regulatory authorities are indeed applied science based on reliable data. McDonagh et al. (2013) addressed the importance of knowledge from regulatory documents for systematic reviews.
The criteria presented in this paper give insight into the considerations concerning relevance and reliability of openly published studies from a regulatory perspective and introduce improvements for better use of the available evidence especially from published literature for risk assessment purposes. Scientific research data fulfilling the described criteria can and indeed should -Parametric tests are mostly considered more sensitive compared to non-parametric, but may not be applicable.
-Trend-testing/regression across many dose groups may be more sensitive compared to group-wise comparison. 4 Are the statistical tests chosen appropriate?
-Statistical tests make assumptions on sample and population data. If these are violated (appropriate initial testing e.g. for normality and equal variance in case of ANOVA), the test is not appropriate and another test relying on fewer/other assumptions should be used. 5 Have regression models been applied, can they be considered appropriate?
-When regression methods are applied for parameter calculation, e.g. benchmark doses or flux values, there should be either biological or empirical evidence for the appropriateness of the underlying assumption in the specific case. 6 Have confounding effects been taken into consideration?
-Confounding effects can be taken into consideration in the statistical analysis itself and/or interpretation of the statistical evaluation.
be used in risk assessments. As such, said data might also have a much greater impact on regulatory decision making. The application of the methods and criteria described here could increase the database used in substance approval and product authorisation. In addition, the presented criteria aim at a better understanding of assessments by interested parties or the public.
